
WVE
Wave Life Sciences develops medicines using nucleic acid-based therapies, primarily antisense oligonucleotides and similar modalities, to treat genetic and neurological diseases. The company is in clinical and preclinical development stages, testing multiple product candidates with the goal of obtaining regulatory approvals and eventually commercializing treatments. Wave is advancing a pipeline of candidates while seeking partnerships and financing to support ongoing research, development, and future manufacturing and marketing efforts.